Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and reading ability in wet age-related macular degeneration
2010-024001-12Phase 4Terminated
- Sponsor
- Turku University Hospital
- Start
- Dec 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab in age-related macular degeneration (AMD), sponsored by Turku University Hospital. Primary endpoint: Reading ability and visual function at 12 months. Started Dec 2010; status: terminated.
02
Drugs
bevacizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2010-024001-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024001-12.